scispace - formally typeset
W

Wei Liu

Researcher at Agios Pharmaceuticals

Publications -  57
Citations -  10239

Wei Liu is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Proline oxidase & Proline dehydrogenase. The author has an hindex of 28, co-authored 48 publications receiving 8465 citations. Previous affiliations of Wei Liu include Shanghai Jiao Tong University & University of Toledo.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Maria E. Figueroa, +25 more
- 14 Dec 2010 - 
TL;DR: Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specificHypermethylation signature, suggesting a shared proleukemogenic effect.
Journal ArticleDOI

Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.

Wei Liu, +6 more
- 05 Jun 2012 - 
TL;DR: Using MYC-inducible human Burkitt lymphoma model P493 and PC3 human prostate cancer cells, it is shown that MYC suppressed POX/PRODH expression primarily through up-regulating miR-23b*.
Journal ArticleDOI

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Wen-Zhao Zhong, +31 more
- 01 Jan 2018 - 
TL;DR: Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC.
Journal ArticleDOI

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

Katharine E. Yen, +47 more
- 01 May 2017 - 
TL;DR: It is shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development.